TherapeuticsMD Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Years ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(10,278) | $111,997 |
| Less: Income (loss) from discontinued operations, net of tax | (2,579) | 110,923 |
| Net income (loss) from continuing operations | (7,699) | 1,074 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating activities: | ||
| Depreciation and amortization | 922 | 1,193 |
| Share-based payment compensation costs | 1,271 | 11,572 |
| Make-whole payment accretion | — | (354) |
| Other | (129) | (40) |
| Changes in operating assets and liabilities: | ||
| Prepaid and other current assets | 1,999 | 620 |
| Other assets | (1,126) | (7,636) |
| Accounts payable | (2,135) | (1,211) |
| Accrued expenses and other current liabilities | (15,713) | 4,262 |
| Other non-current liabilities | (471) | (121) |
| Total adjustments | (15,382) | 8,285 |
| Net cash provided by (used in) continuing operating activities | (23,081) | 9,359 |
| Cash flows from continuing investing activities: | ||
| Receipts (payment) for patents | — | (355) |
| Net cash used in continuing investing activities | — | (355) |
| Cash flows from continuing financing activities: | ||
| Proceeds from sale of common stock, net of costs | 3,151 | 2,454 |
| Proceeds from sale of common stock related to employee stock purchase plan | — | 14 |
| Repayments of debt | — | (219,432) |
| Proceeds from Series A Preferred Stock, net of transaction costs | — | 21,684 |
| Repurchase of Preferred Stock at liquidation preference | — | (38,657) |
| Proceeds from make-whole derivative | — | 3,322 |
| Repayment of make-whole derivative | — | (2,969) |
| Payment of debt financing fees | — | (1,622) |
| Net cash provided by (used in) continuing financing activities | 3,151 | (235,206) |
| Discontinued operations: | ||
| Net cash used in operating activities | (25,060) | (13,437) |
| Net cash provided by investing activities | — | 223,834 |
| Net cash provided by financing activities | — | — |
| Net cash provided by (used in) discontinued operations | (25,060) | 210,397 |
| Net decrease in cash | (44,990) | (15,805) |
| Cash and restricted cash - continuing operations, beginning of period | 49,317 | 64,907 |
| Cash and restricted cash - discontinued operations, beginning of period | — | 215 |
| Total cash and restricted cash, end of period | $4,327 | $49,317 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $— | $13,545 |
| Supplemental disclosure of noncash financing activities: | ||
| Warrants issued in relation to debt financing agreement | $— | $2,727 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.